E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer

被引:41
作者
Kothandaraman N. [1 ]
Bajic V.B. [2 ]
Brendan P.N.K. [3 ]
Chan Y.H. [4 ]
Keow P.B. [3 ]
Razvi K. [5 ,6 ]
Salto-Tellez M. [3 ]
Choolani M. [1 ]
机构
[1] Diagnostic Biomarker Discovery Laboratory, Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University Health System, 119074
[2] Computational Bioscience Research Center (CBRC), 4700 King Abdullah University of Science and Technology (KAUST)
[3] Department of Pathology, National University Health System, Yong Loo Lin School of Medicine
[4] National University Medical Institutes, Yong Loo Lin School of Medicine, National University Health System
[5] Southend Hospital NHS Trust, Westcliff-on-Sea, Essex
[6] Basildon and Thurrock University Hospital NHS, Foundation Trust, Basildon, Essex
基金
英国医学研究理事会;
关键词
Ovarian Cancer; Ovarian Epithelial Cancer; Serous Carcinoma; Malignant Case; Benign Case;
D O I
10.1186/1471-2407-10-64
中图分类号
学科分类号
摘要
Background: Ovarian epithelial cancer (OEC) usually presents in the later stages of the disease. Factors, especially those associated with cell-cycle genes, affecting the genesis and tumour progression for ovarian cancer are largely unknown. We hypothesized that over-expressed transcription factors (TFs), as well as those that are driving the expression of the OEC over-expressed genes, could be the key for OEC genesis and potentially useful tissue and serum markers for malignancy associated with OEC.Methods: Using a combination of computational (selection of candidate TF markers and malignancy prediction) and experimental approaches (tissue microarray and western blotting on patient samples) we identified and evaluated E2F5 transcription factor involved in cell proliferation, as a promising candidate regulatory target in early stage disease. Our hypothesis was supported by our tissue array experiments that showed E2F5 expression only in OEC samples but not in normal and benign tissues, and by significantly positively biased expression in serum samples done using western blotting studies.Results: Analysis of clinical cases shows that of the E2F5 status is characteristic for a different population group than one covered by CA125, a conventional OEC biomarker. E2F5 used in different combinations with CA125 for distinguishing malignant cyst from benign cyst shows that the presence of CA125 or E2F5 increases sensitivity of OEC detection to 97.9% (an increase from 87.5% if only CA125 is used) and, more importantly, the presence of both CA125 and E2F5 increases specificity of OEC to 72.5% (an increase from 55% if only CA125 is used). This significantly improved accuracy suggests possibility of an improved diagnostics of OEC. Furthermore, detection of malignancy status in 86 cases (38 benign, 48 early and late OEC) shows that the use of E2F5 status in combination with other clinical characteristics allows for an improved detection of malignant cases with sensitivity, specificity, F-measure and accuracy of 97.92%, 97.37%, 97.92% and 97.67%, respectively.Conclusions: Overall, our findings, in addition to opening a realistic possibility for improved OEC diagnosis, provide an indirect evidence that a cell-cycle regulatory protein E2F5 might play a significant role in OEC pathogenesis. © 2010 Kothandaraman et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 57 条
[1]  
Bristow R.E., Berek J.S., Surgery for ovarian cancer: how to improve survival, Lancet, 367, 9522, pp. 1558-1560, (2006)
[2]  
Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J., Cancer statistics, 2008, CA Cancer J Clin, 58, 2, pp. 71-96, (2008)
[3]  
Holschneider C.H., Berek J.S., Ovarian cancer: epidemiology, biology, and prognostic factors, Semin Surg Oncol, 19, 1, pp. 3-10, (2000)
[4]  
Kristensen G.B., Trope C., Epithelial ovarian carcinoma, Lancet, 349, 9045, pp. 113-117, (1997)
[5]  
Bast R.C., Xu F.J., Yu Y.H., Barnhill S., Zhang Z., Mills G.B., CA 125: the past and the future, Int J Biol Markers, 13, 4, pp. 179-187, (1998)
[6]  
Partridge E., Kreimer A.R., Greenlee R.T., Williams C., Xu J.L., Church T.R., Kessel B., Johnson C.C., Weissfeld J.L., Isaacs C., Et al., Results from four rounds of ovarian cancer screening in a randomized trial, Obstet Gynecol, 113, 4, pp. 775-782, (2009)
[7]  
Menon U., Gentry-Maharaj A., Hallett R., Ryan A., Burnell M., Sharma A., Lewis S., Davies S., Philpott S., Lopes A., Et al., Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), Lancet Oncol, 10, 4, pp. 327-340, (2009)
[8]  
Liu Y., Ganesan T.S., Tumour suppressor genes in sporadic epithelial ovarian cancer, Reproduction, 123, 3, pp. 341-353, (2002)
[9]  
Fehrmann R.S., Li X.Y., Zee A.G., de Jong S., Te Meerman G.J., de Vries E.G., Crijns A.P., Profiling studies in ovarian cancer: a review, Oncologist, 12, 8, pp. 960-966, (2007)
[10]  
Lu K.H., Patterson A.P., Wang L., Marquez R.T., Atkinson E.N., Baggerly K.A., Ramoth L.R., Rosen D.G., Liu J., Hellstrom I., Et al., Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis, Clin Cancer Res, 10, 10, pp. 3291-3300, (2004)